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Pascular Effects of Sirolimus-Eluting
ersus Bare-Metal Stents in Diabetic Patients
hree-Dimensional Ultrasound Results of the Diabetes
nd Sirolimus-Eluting Stent (DIABETES) Trial
ilar Jiménez-Quevedo, MD,* Manel Sabaté, MD, PHD,* Dominick J. Angiolillo, MD,†
arco A. Costa, MD, PHD,† Fernando Alfonso, MD, PHD,* Joan Antoni Gómez-Hospital, MD, PHD,‡
osana Hernández-Antolín, MD, PHD,* Camino Bañuelos, MD,* Javier Goicolea, MD, PHD,§
rancisco Fernández-Avilés, MD, PHD, Theodore Bass, MD, Javier Escaned, MD, PHD,*
aul Moreno, MD,* Cristina Fernández, MD, PHD,* Carlos Macaya, MD, PHD,*
or the DIABETES Investigators
adrid, Barcelona, Vigo, and Valladolid, Spain; and Jacksonville, Florida
OBJECTIVES A predefined intravascular ultrasound (IVUS) substudy was performed to evaluate the
vascular effects of sirolimus-eluting stent (SES) versus bare-metal stent (BMS).
BACKGROUND The Diabetes and Sirolimus-Eluting Stent (DIABETES) trial is a prospective, multicenter,
randomized, controlled trial aimed at demonstrating the efficacy of the SES compared with
BMS in diabetic patients.
METHODS Serial intravascular ultrasound analyses were performed in 140 lesions (SES  75; BMS 
65) immediately after stent implantation and at nine-month follow-up. Vessel, luminal, and
stent mean areas and volumes were evaluated at both edges and within the stented segment.
Qualitative assessment of residual dissections and stent apposition were also performed.
RESULTS Baseline clinical and angiographic characteristics were similar between groups. At 9 months,
in-stent neointimal hyperplasia (NIH) mean area and volume were significantly reduced in
the SES group (median NIH area 0.01 mm2 [0.0 to 0.1] vs. 2.0 mm2 [1.0 to 2.9] and median
NIH volume 0.11 mm3 [0 to 2.1] vs. 35.3 mm3 [16.6 to 62.6]; both p  0.0001). In the SES
group, stent edges evidenced significant increase in lumen dimensions mainly due to
significant increase in vessel volume, whereas those of the BMS group presented vessel
shrinkage leading to significant lumen reduction. Late acquired incomplete stent apposition
was observed in 11 lesions (14.7%) in the SES group and 0 in the BMS group (p  0.001).
At one year, no stent thromboses occurred in malapposed stents.
CONCLUSIONS The SES implantation effectively inhibits NIH in diabetic patients. The antirestenotic effect
of SES is also appreciated at the stent edges. Late acquired stent malapposition is a frequent
phenomenon in diabetic patients treated with SES. (J Am Coll Cardiol 2006;47:2172–9)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.063© 2006 by the American College of Cardiology Foundation
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tespite advances in the medical treatment and revascular-
zation procedures, coronary artery disease remains a leading
ause of morbidity and mortality in diabetic patients (1).
iabetic patients often present unfavorable coronary
natomy with small and diffusely diseased vessels (2) and
xhibit different healing response after stent implantation
s compared with nondiabetics (3). The sirolimus-eluting
tent (SES) has been demonstrated to reduce restenosis in
elected patients with de novo coronary lesions (4,5). Ret-
ospective subgroup analyses of pivotal clinical trials have
uggested that SES may be effective in diabetic patients
6,7). However, the potent antiproliferative effect of SES
8), which markedly inhibits neointimal hyperplasia (NIH)
4,5), may also induce deleterious local phenomena such
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iménez-Quevedo is a recipient of a Community of Madrid-European Social Funding
rant.n
Manuscript received October 31, 2005; revised manuscript received December 29,
005, accepted January 16, 2006.s necrosis or apoptosis (9), which potentially affect the
laque behind the stent and the vessel wall (10). Volu-
etric intravascular ultrasound (IVUS) provides comple-
entary information on the extent of neointimal prolif-
ration, arterial remodeling, and collateral effects such as
dge restenosis and incomplete stent apposition (ISA). To
ate, few data of the mechanistic effects of SES in diabetics
ave been reported. The Diabetes and Sirolimus-Eluting Stent
DIABETES) trial is the first randomized multicenter study to
ompare the outcomes of diabetic patients treated with SES
ersus bare-metal stents (BMS) (11).
The aim of the present study was to evaluate the vascular
ffects of SES compared with BMS by means of serial
hree-dimensional volumetric IVUS analyses as well as to
eport the one-year clinical results in patients enrolled in the
IABETES trial.
ETHODS
atient selection. Between February and December 2003,
he DIABETES trial enrolled 160 diabetic patients with de
ovo coronary stenoses (2.25 to 4.0 mm in diameter by
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June 6, 2006:2172–9 The DIABETES Trial: IVUS Outcomesisual estimation) located in one, two, or three vessels to
eceive either SES (Cypher, Cordis, Miami, Florida) or
MS (Velocity, Cordis) implantation. A total of 221
oronary stenoses were treated in this trial (111 lesions in 80
atients with Cypher stents and 110 lesions in 80 patients
ith Velocity stents). There were no exclusions based on
esion length or presence of chronic total occlusions. The
IABETES study protocol has been described in detail
lsewhere (11). Clopidogrel was maintained for one year in
ll randomized patients. The current IVUS study was
respecified in the DIABETES trial protocol, and the goal
as to obtain a minimum of 60% of the implanted stents
ssessed by IVUS. The study was approved by the institu-
ional review board of each participating center, and all
atients signed a written informed consent.
olumetric IVUS. The IVUS studies were performed with
40-MHz mechanical system (Atlantis; Boston Scientific,
atick, Massachusetts). Images were acquired during a
otorized pullback of the IVUS probe at a constant speed
f 0.5 mm/s, after intracoronary administration of 0.1 to 0.2
g nitroglycerin, after the procedure, and at nine-month
ollow-up. All IVUS procedures were recorded on super-
HS videotapes. Qualitative and quantitative volumetric
VUS analyses were performed by an independent core
aboratory (University of Florida Cardiovascular Imaging
Table 1. Baseline Clinical Characteristics Betw
All Randomized
(n  160)
Age, yrs 66.5  9
Male gender 100 (62.5)
Insulin-dependent 53 (33.1)
Non–insulin-dependent 107 (66.9)
Hyperlipidemia 98 (61.3)
Hypertension 106 (66.3)
Smoking 76 (47.5)
Body mass index, % 29.1  4
Prior MI 59 (36.9)
Prior revascularization 30 (18.7)
Exertional angina 48 (30.0)
Unstable angina 92 (57.5)
Multivessel disease 104 (65.0)
Ejection fraction, % 65.4  13
Glycated hemoglobin A1c, % 7.3  1.4
Abbreviations and Acronyms
BMS  bare-metal stent
DIABETES  Diabetes and Sirolimus-Eluting Stent
trial
EEM  external elastic membrane
ISA  incomplete stent apposition
IVUS  intravascular ultrasound
NIH  neointimal hyperplasia
SES  sirolimus-eluting stentData are mean  SD or n (%).
BMS  bare-metal stent; IVUS  intravascular ultrasound; More Laboratories, Jacksonville, Florida) using a methodol-
gy previously reported (12). The analysts were blinded to
reatment allocation. The stented coronary segments and
oth edges (5 mm adjacent to the distal and proximal stent
orders) were selected for quantitative and qualitative anal-
sis. Quantitative three-dimensional IVUS analysis was
erformed using a dedicated quantitative intravascular ul-
rasound analysis system (QIVA, Pie Medical Imaging,
aastricht, the Netherlands) (12). Lumen, stent, and ex-
ernal elastic membrane (EEM) areas were measured along
he entire stented and edge segments. Volumes were deter-
ined from a summation of measured cross-sectional areas
n all frames of the pullback region based on Simpson’s rule
12).
In-stent NIH volume was calculated as stent volume
inus luminal volume at nine-month follow-up. Percent
IH volume was defined as the ratio of NIH volume to the
tent volume multiplied by 100. Mean in-stent NIH area
as calculated as in-stent NIH volume divided by stent
ength. For totally occluded vessels at follow-up, which were
ot associated with stent thrombosis, it was estimated that
he entire length of the stent was filled with NIH (13).
Incomplete stent apposition was defined as 1 strut
learly separated from the vessel wall, with evidence of blood
peckling behind the stent struts without overlapping side
ranches (14). To define ISA, consensus between two
ndependent analysts blinded to treatment allocation was
equired. On the basis of serial intravascular analyses ISA
as classified into three categories: 1) resolved: ISA present
t baseline but no longer at follow-up; 2) persistent: ISA
resent at baseline and at nine-month follow-up; and 3) late
cquired: ISA not present at baseline but present at nine-
onth follow-up. In the segment with ISA, the lumen
ontour was delineated outside the stent contour. Lumen
rea outside of the stent was also measured (ISA area).
urther, vessel, stent, and lumen mean areas and volumes
IVUS-Assessed Groups
S-SES Group
(n  62)
IVUS-BMS Group
(n  55) p Value
65.4  8 67.1  9 0.31
42 (67.7) 34 (61.8) 0.50
16 (25.8) 19 (34.5) 0.30
46 (74.2) 36 (65.5) 0.30
42 (67.7) 34 (61.8) 0.50
37 (59.7) 37 (67.3) 0.39
31 (50) 29 (52.7) 0.77
28.5  4 28.6  3 0.92
19 (30.6) 25 (45.5) 0.10
12 (19.3) 11 (20) 0.94
19 (30.6) 16 (29.1) 0.86
35 (56.5) 26 (47.2) 0.42
38 (61.3) 38 (69.1) 0.38
67.9  12 64.8  14 0.20
7.3  1.6 7.3  1.4 0.85een
IVUI  myocardial infarction; SES  sirolimus-eluting stent.
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The DIABETES Trial: IVUS Outcomes June 6, 2006:2172–9ere measured in both the ISA and the non-ISA segments
ithin the stent.
linical follow-up. After discharge, clinical follow-up was
btained at 1, 9, and at 12 months. At 12 months,
lopidogrel was withdrawn in all patients who did not
eceive additional revascularization during follow-up.
tatistical analysis. The sample size for this prespecified
VUS substudy was calculated for a difference of 30% in the
ean in-stent NIH area between the groups (estimated for
mean in-stent NIH area of 2.2 mm2 in the BMS arm vs.
.5 mm2 in the SES arm), with a standard deviation of 1.5,
lpha error of 0.05, and beta error of 0.20 (13). Thus, a
inimum of 105 lesions were prespecified for enrollment to
llow for 25% attrition due to noncompliance with invasive
ollow-up procedures, IVUS technical failures, and subop-
imal IVUS quality.
Data are presented as frequencies, mean  1 SD, or
edian (interquartile range). Following evaluation of nor-
al distribution (Kolmogorov-Smirnov test), comparisons
etween BMS and SES stents were performed with two-
ailed, unpaired t tests for continuous parameters, paired
tests for change from post-procedure to follow-up, or
edian comparisons when applicable using the median test.
ategoric variables were compared by means of the chi-
quare test or Fisher exact test when at least 25% of values
howed an expected cell frequency below 5. Significance was
et at alpha of 0.05.
ESULTS
aseline characteristics. One hundred seventeen patients
140 lesions) were included in this IVUS substudy. This
ohort involved 73% of patients included in the trial. We
ould not perform IVUS in 81 lesions. Main reasons
able 2. Baseline Angiographic Characteristics Between Groups
IVUS
SES Group
(n  75)
BMS Grou
(n  65)
reated artery
LAD 26 (34.7) 27 (41.5)
LCX 14 (18.7) 12 (18.5)
RCA 35 (46.7)* 26 (40)†
esion length, mm 14.8  8.7 15.9  7.7
eference diameter, mm 2.4  0.5* 2.5  0.6
inimal luminal diameter, mm 0.9  0.4 0.9  0.4
ercentage diameter stenosis, % 61.5  17 60.4  14
hronic total occlusion 11 (14.7) 5 (7.7)†
2/C class lesion 60 (80) 52 (80)
n-segment LL, mm 0.01  0.3 0.5  0.4
n-stent LL, mm 0.05  0.3 0.7  0.5
roximal reference LL, mm 0.0005  0.3 0.07  0.4
istal reference LL, mm 0.08  0.3 0.04  0.4
n-segment restenosis rate 3 (4.1)* 17 (27)
n-stent restenosis rate 1 (1.4) 16 (25.4)
ata presented as number (%) mean  SD. p  0.05 between stents evaluated by I
LAD  left anterior descending; LCX  left circumflex artery; LL  late loss;ncluded very small vessel size (n 53; 66%), distal location
†f the target stent in tortuous vessels (n  19; 23%), and
iffuse disease distal from the target stent (n  9; 11%).
Baseline demographic and angiographic characteristics of
his subset of patients were comparable between SES and
MS groups (Tables 1 and 2). This cohort of patients
ssessed by IVUS presented similar baseline clinical char-
cteristics to those not evaluated by IVUS. However, from
he angiographic point of view, lesions evaluated by IVUS
videnced larger vessel size and more often were located in
he right coronary artery both in the SES and in the BMS
roup. Besides, in the BMS group, IVUS-assessed stents
ere less often implanted in chronic total occlusions than in
hose without IVUS assessment. In terms of outcomes,
tents studied by IVUS presented less frequent restenosis at
ollow-up. The length of restenotic segment was similar
etween lesions assessed or not by IVUS (18.7 10 mm vs.
8.2  11 mm, respectively, in the BMS group; p  0.69;
able 3. IVUS Parameters Within the Stented Segment
IVUS-SES
Group
(n  75)
IVUS-BMS
Group
(n  65) p Value
ean EEM area, mm2
Post-procedure 15.8  4.8 16.2  4.9 0.72
9-month follow-up 16.7  4.3* 16.5  4.9 0.87
ean stent area, mm2
Post-procedure 7.4  2.3 8.0  2.5 0.27
9-month follow-up 7.7  2.3 7.9  2.6 0.71
ean lumen area, mm2
Post-procedure 7.4  2.3 8.0  2.5 0.27
9-month follow-up 7.7  2.4 5.3  2.5† 0.001
ata presented as mean  SD. Means compared by unpaired Student t test
etween groups and by paired Student t test between post-procedure and follow-up
Kolmogorov-Smirnov test not significant). *p  0.04 post-procedure vs. follow-up;
and Without IVUS
No IVUS
p Value
SES Group
(n  36)
BMS Group
(n  45) p Value
0.40 17 (47.2) 21 (46.7) 0.96
0.97 10 (27.8) 14 (31.1) 0.74
0.42 9 (25) 10 (22.2) 0.77
0.59 13.9  7.1 14.4  7.4 0.79
0.47 2.1  0.5 2.1  0.4 0.76
0.49 0.8  0.4 0.7  0.4 0.16
0.68 58.8  18.3 65.9  18.6 0.09
0.20 3 (8.3) 10 (22.2) 0.09
1.00 28 (77.8) 37 (82.2) 0.62
0.001 0.16  0.5 0.43  0.5 0.04
0.001 0.18  0.5 0.6  0.5 0.002
0.33 0.12  0.3 0.01  0.4 0.22
0.034 0.08  0.3 0.08  0.5 0.97
0.001 5 (17.2) 17 (44.7) 0.01
0.001 3 (10.3) 16 (42.1) 0.004
nd those not analyzed by IVUS *in the SES group and †in the BMS group.
 right coronary artery; other abbreviations as in Table 1.With
p
†
†p  0.0001 post-procedure vs. follow-up.
EEM  external elastic membrane; other abbreviations as in Table 1.
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June 6, 2006:2172–9 The DIABETES Trial: IVUS Outcomes1.8  7 mm vs. 12.0  8 mm, respectively, in the SES
roup; p  0.76). Occlusive restenoses were not interro-
ated by IVUS (one in the SES group and six in the BMS
roup). Finally, two stents in the SES group and one in the
MS group with edge effect were not studied by IVUS.
At nine-month angiographic follow-up, 112 patients
134 lesions) were reassessed by IVUS (95.7% of the eligible
atients and lesions).
tented segment IVUS analysis. Post-procedure IVUS
arameters were similar between groups (Table 3). There
as an increase in EEM area from post-procedure to
igure 1. (Top panels) Histograms of neointima hyperplasia (NIH) volu
BMS) group (right). A non-Gaussian distribution is demonstrated in bot
MS group). The median test evidenced significant differences between g
roup (left) and the BMS group (right). A non-Gaussian distribution is demonstra
.03 for BMS group). The median test evidenced significant differences betweeollow-up in the SES group (15.8  4.8 mm2 to 16.7  4.3
m2 from post-procedure to follow-up; p  0.04). In the
MS group, mean lumen area was significantly reduced
rom post-procedure to follow-up (8.0  2.5 mm2 to 5.3 
.5 mm2; p  0.001). The NIH median area and volume
ere significantly reduced in the SES group as compared to
he BMS group (median NIH area 0.01 mm2 [0.0 to 0.1] vs.
.0 mm2 [1.0 to 2.9]; median NIH volume 0.11 mm3 [0.0
o 2.1] vs. 35.3 mm3 [16.6 to 62.6]; both p  0.0001).
igure 1 depicts the non-gaussian distribution of main
VUS volumetric outcomes between groups, with the marked
the sirolimus-eluting stent (SES) group (left) and the bare-metal stent
ups (Kolmogorov-Smirnov test: p  0.0001 for SES group; p  0.02 for
. (Bottom panels) Histograms of percent volume obstruction in the SESme in
h gro
roupsted in both groups (Kolmogorov-Smirnov test: p 0.0001 for SES group;
n groups.
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The DIABETES Trial: IVUS Outcomes June 6, 2006:2172–9ifference observed between mean and median values especially
n the SES group.
More than 50% of segments treated with SES evidenced
irtually no NIH (Fig. 1). Neointimal hyperplasia inhibition
y SES was independent of the diabetes status and stent size
nd length (Table 4).
dge effect. Volumetric analysis of the stent edges dem-
nstrated a different pattern of vascular changes between
roups (Fig. 2). In the SES group, a significant increase in
EM volume (vessel enlargement) could encompass an
ncrease in plaque volume, resulting in discrete net luminal
nlargement. Conversely, in the BMS group, negative
emodeling of the EEM led to net luminal reduction despite
he absence of plaque growth. This pattern of vascular
ehavior was similar in either edge.
SA, coronary aneurysm, and edge tears. Overall, the
ncidence of ISA was significantly higher in the SES group
han in the BMS group (n  22 [29%] vs. n  5 [7.7%];
 0.001). This phenomenon occurred mainly as a result of
n increased incidence of late acquired ISA in the SES
roup (n  11 [14.7%] vs. n  0 [0%]; p  0.001).
dditionally, four patients (three in the SES group and one
n the BMS group) also presented ISA at follow-up.
owever, because their baseline studies were not available
or serial comparison, they were not accounted as late
cquired ISA. There were no significant differences between
roups in both resolved (n  0 [0%] in the SES group vs.
 2 [3.1%] in the BMS group; p  0.2) and persistent
SA (n  8 [10.7%] in the SES group vs. n  2 [3.2%] in
he BMS group; p  0.1). An example of late acquired ISA
able 4. Neointimal Proliferation per Diabetes Status, Stent
ength, and Stent Diameter
IVUS-SES
Group
(n  75)
IVUS-BMS
Group
(n  65) p Value
IH area, mm2
IDDM 0.01 (0–0.03) 2.61 (1.7–3.9) 0.001
NIDDM 0.005 (0–0.1) 1.55 (0.6–2.6) 0.001
Stent size
2.5 mm 0 (0–0.02) 1.1 (0.7–2.1) 0.001
2.5 mm 0.01 (0–0.1) 2.2 (1.2–3.3) 0.001
Stent length
20 mm 0 (0–0.04) 2.0 (0.9–2.9) 0.001
20 mm 0.01 (0–0.1) 1.9 (1.1–3.1) 0.001
IH volume, mm3
IDDM 0.1 (0–0.4) 44.7 (33.2–82.1) 0.001
NIDDM 0.07 (0–2.9) 29.9 (13.6–62.3) 0.001
Stent size
2.5 mm 0 (0–0.2) 20.6 (9.8–30.4) 0.001
2.5 mm 0.1 (0–2.8) 42.3 (23.9–69.9) 0.001
Stent length
20 mm 0 (0–0.5) 29.9 (10.3–47.8) 0.001
20 mm 0.66 (0–39.0) 55.2 (29.8–87.9) 0.001
ata presented as median (interquartile range).
IDDM  insulin-dependent diabetes mellitus; NIDDM  non–insulin-
ependent diabetes mellitus; NIH neointimal hyperplasia; other abbreviations as in
able 1.s depicted in the Figure 3. dTo determine the main mechanism of the three types of
SA, a quantitative analysis of the lumen and EEM areas
pecifically at the malapposition sites was performed and
ompared with the corresponding segments of the post-
rocedure IVUS pullback. In addition, we compared lumen
nd EEM areas at the malapposition site (ISA segment)
ith the remaining part of the stent without malapposition
non-ISA segment). In those lesions with late acquired ISA
n  11) a significant increase in lumen and vessel mean
reas at the ISA segment were observed from post-
rocedure to follow-up (mean lumen area 7.5 1.9 mm2 vs.
.8 1.5 mm2; p 0.04; mean EEM area 16.6 3.9 mm2
s. 19.2  2.9 mm2; p  0.03). In addition, mean lumen
nd EEM areas were significantly larger at the ISA segment
ompared with non-ISA segments (mean lumen area 8.8 
.5 mm2 vs. 7.5  1.2 mm2; p  0.02; mean EEM area
9.2 2.9 mm2 vs. 16.7 2.8 mm2; p 0.03). Thus, local
ositive remodeling appeared to be involved in the mecha-
ism of late acquired ISA in diabetic patients. Late acquired
SA was mainly localized at stent edges (73%).
Overall, stents with persistent malapposition (n 10) did
ot evidence significant changes in EEM or lumen mean
reas between post-procedure and follow-up (lumen area
.9  2.7 mm2 vs. 8.8  3.7 mm2; p  0.9; EEM area
8.4  5.9 mm2 vs. 18.7  5.8 mm2; p  0.8). Finally,
tents with resolved ISA (n  2) presented an increase in
ean plaque area (delta change 5.9 mm2) and virtually, no
odification in mean EEM area (delta change 0.6 mm2).
s a result, mean lumen area was reduced at follow-up
delta change 4.3 mm2).
None of the segments assessed by IVUS evidenced
oronary aneurysm. Resolved and persistent rates of edge
ears were comparable between groups (SES vs. BMS: 3.9%
s. 6.5% [p  0.7] and 2.6% vs. 0% [p  0.5], respectively).
linical outcomes at one year. One-year clinical follow-up
f the entire population included in the DIABETES trial was
vailable in all patients (100%). Overall, the incidence of
ajor adverse cardiac events was significantly lower in the
ES group (Table 5).
At one year, all patients (100%) were on treatment
ith clopidogrel. The subacute (from 24 h to 30 days
fter the index procedure) and late (beyond 30 days after
he index procedure) stent thrombosis rates were 0% in
he SES group up to one-year follow-up. There were two
tent thromboses in the BMS group, one subacute and
ne late; the first occurred while the patient was on dual
ntiplatelet therapy and the latter one week after tran-
ient clopidogrel withdrawal (due to gastrointestinal sur-
ery) two months after the index procedure. Only one
atient with late acquired ISA underwent nonclinically
riven target lesion revascularization based on the IVUS
ndings. Following clopidogrel withdrawal at one year,
here was no reported stent thrombosis associated with
ocumented ISA.
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June 6, 2006:2172–9 The DIABETES Trial: IVUS OutcomesISCUSSION
his is the first randomized blinded IVUS study in patients
ith diabetes mellitus to evaluate the antirestenotic effect of
ES compared with BMS. Compared with the BMS group,
iabetic patients treated with SES evidenced a marked
eduction in NIH volume within the stented segment. This
tudy also demonstrated an enhanced compensatory vessel
nlargement at both proximal and distal edges and a
ignificantly higher incidence of late acquired ISA associ-
ted with the implantation of SES. Finally, the clinical
eneficial effect of SES implantation in this cohort of
iabetic patients with small coronary arteries persisted up to
he one-year follow-up. This is in accordance with the
ndings of the cohort of diabetic patients included in the
irolimus-Eluting Stent and a Standard Stent in the Pre-
ention of Restenosis in Small Coronary Arteries (SES-
MART) study (15,16).
The NIH was similarly inhibited in both insulin and
on–insulin-dependent diabetics treated with SES. The
elative reduction in NIH volume was higher in the insulin-
ependent group, which was likely owing to a higher
roliferative response observed in the BMS group. The
ubanalyses of the Sirolimus-Eluting Stent in Coronary
igure 2. Patterns of vascular changes at proximal (top panels) and distal e
reduction in external elastic membrane [EEM] volume), led to a redu
irolimus-eluting stent group (right), vessel enlargement (increase in EEM
umen volume. *p  0.09; †p  0.04; ‡p  0.05; §p  0.001; ¶p  0.03esions (SIRIUS) and SES-SMART trials (7,16) suggested treduced antiproliferative effect of SES in insulin-
ependent diabetics, mainly related to restenosis at the stent
dges (peri-stent). Such a hypothesis was not confirmed in
he overall DIABETES trial and in the present IVUS
ubstudy. The higher degree of NIH suppression demon-
trated in insulin-dependent lesions may indicate that in the
bsence of peri-stent restenosis (7,16), rapamycin may be
ven more efficacious in this subgroup which usually pre-
ents an exacerbated proliferative response to stent implan-
ation (3).
Opposite patterns of changes in EEM were observed at
he edge segments in vessels treated with SES versus BMS
Fig. 2). As a result, lumen was preserved in the edge
egments of patients treated with SES. Vessel shrinkage or
ack of positive remodeling has been previously observed at
he edges after BMS implantation (17,18). Whether the
resent IVUS findings are associated with a beneficial
ascular effect of sirolimus at unstented adjacent coronary
egments remains to be demonstrated. Interestingly, both
roups in the present study showed minimal plaque prolif-
ration at the edges, which may be related to stent deploy-
ent techniques used in this trial. In the DIABETES trial,
udicious stent deployments with special attention to cover
bottom panels). In the bare-metal stent group (left), negative remodeling
in luminal volume despite small reductions in plaque volume. In the
me) encompassed an increase in plaque volume, resulting in a net gain in
t-procedure versus 9-month follow-up p values).dges (
ctionhe entire diseased segment and avoid trauma outside the
s
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19,20).
The incidence of late acquired ISA was markedly in-
reased in the SES group. This phenomenon was associated
ith local vessel enlargement at ISA sites. Recently, in the
IRIUS trial (21), late acquired ISA was documented in
.7% of stents evaluated with IVUS and it was mainly
ocated at the middle portion of the stent. Conversely, in our
igure 3. (Top) Intravascular imaging of a stent completely apposed imm
ollow-up: Late acquired incomplete stent apposition is evidenced.
Table 5. Clinical Events at One-Year Follow-U
SES Group
(n  80)
Cardiac death 1 (1.3)
MI 2 (2.5)
Non–Q-wave 1 (1.3)
Q-wave 1 (1.3)
TLR,* 5 (6.3)
PCI 5 (6.3)
Bypass graft surgery 0 (0)
All events,† 8 (10)
Stent thrombosis 0 (0)
0–30 days 0 (0)
31–365 days 0 (0)
Data presented as number of patients (%). *In-segment zon
CI  confidence interval; MI  myocardial infarction; PCI 
revascularization; other abbreviations as in Table 1.rial late acquired ISA was mainly located at stent edges.
he positive remodeling appeared to be the main cause of
SA, which was extended beyond the boundaries of the
tent, leading to a beneficial vascular effect at the edges (Fig. 2).
n the other hand, trials by the use of paclitaxel-eluting
tent demonstrated similar rates of ISA as compared with
MS (22). Late acquired ISA may be related to localized
ypersensitivity response to the polymer that remains in situ
ely after the implantation. (Bottom) Same artery imaging at nine-month
Group
 80)
Relative Risk
(95% CI) p Value
(2.5) 0.66 (0.13–3.31) 1.00
(7.5) 0.49 (0.14–1.63) 0.28
(7.5) 0.28 (0.04–1.71) 0.12
(0) Undefined 1.00
(35) 0.25 (0.11–0.58) 0.001
(33.8) 0.27 (0.12–0.60) 0.001
(1.3) Undefined 1.00
(38.8) 0.34 (0.18–0.65) 0.001
(2.5) Undefined 1.00
(1.3) Undefined 1.00
(1.3) Undefined 1.00
lusive events.p
BMS
(n
2
6
6
0
28
27
1
31
2
1
1
e; †exc
percutaneous coronary intervention; TLR  target lesion
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June 6, 2006:2172–9 The DIABETES Trial: IVUS Outcomesfter complete drug release (23). Eventually, diabetes mel-
itus as a proinflammatory disease (24) may exhibit an
nhanced inflammatory reaction after drug-eluting stent
mplantation. However, at present no data exist regarding a
igher incidence of late acquired ISA after SES implanta-
ion in diabetics than in nondiabetics. Other plausible
echanistic explanations for the ISA phenomenon include
ash-out of plaque or thrombus entrapped behind the stent
truts after the procedure, tissue necrosis, and positive vessel
emodeling associated with the lack of NIH (10). Although no
hrombotic event was associated with ISA even after with-
rawal of clopidogrel, a word of caution must be given to keep
hese patients under clinical control given the possibility of the
ccurrence of very late stent thrombosis (25).
tudy limitations. The main limitation of this study is the
otential selection bias inherent to any IVUS evaluation.
herefore, this data can not be extrapolated to the diabetic
opulation with vessels not amenable for IVUS assessment.
owever, in this DIABETES IVUS substudy 70% of
atients could be assessed by IVUS and no baseline clinical
r angiographic differences were observed between SES and
MS groups. Also, IVUS assessment was performed in only
hree out of eight SES presenting with restenosis (Table 2).
herefore, we cannot extrapolate these findings to the entire
ohort of restenotic SES. This is also an inherent limitation
f any IVUS study, especially when one tries to avoid the
ndesirable risk of inducing a nonclinically driven target
esion revascularization.
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